GNAS and pancreatic intraductal papillary-mucinous neoplasm: This review highlights the difficulty in differentiating low-risk from high-risk IPMNs and underscores the significance of biomarkers such as KRAS and GNAS mutations, which are directly linked to IPMN progression.